Cancer Advisor

Cancer treatment is evolving faster than ever. From cutting-edge immunotherapies to AI-driven diagnostics, the discoveries of 2026 are reshaping how clinicians detect, monitor, and treat malignancies. These breakthroughs offer hope for longer survival, improved quality of life, and personalized therapies tailored to each patient. The 2026 American Association of Cancer Research (AACR) Annual Meeting took place in San Diego from April 17-22 and reflected how cancer research continues to evolve. Progress is increasingly driven by how advances across biology, technology, and policy come together to shape how we understand disease, develop new treatments, and bring them into practice. A central theme this year was the continued focus on cancer as more than just a collection of tumor cells. It is shaped by a complex ecosystem — immune cells, surrounding tissue, metabolism, and even the microbiome — all interacting in dynamic ways. Credit:  Statista 1. Immunotherapy: Expanding Beyond Che...

Originally compiled for translational precision oncology tracking. References to clinical registries provided inline. Pembrolizumab (Keytruda) has fundamentally shifted the treatment paradigm for advanced malignancies by blocking the Programmed Death-1 (PD-1) receptor. However, clinical data shows that up to 60–70% of patients experience either primary resistance (lack of initial response) or adaptive secondary resistance (progression after a period of response). Accumulating clinical evidence points to the Tumor Microenvironment (TME) as the principal driver of this therapeutic failure. This review synthesizes the cell-extrinsic and cell-intrinsic mechanisms within the TME that neutralize cytotoxic T-cell activity and maps out strategic metabolic and microenvironmental interventions to restore anti-PD-1 sensitivity. 1. Introduction: The Mechanism of Immune Checkpoint Blockage (ICB) The therapeutic rationale behind pembrolizumab relies on a simple premise: unmask...

OneDayMD  |  Integrative Oncology Review ISSN (Online) pending  •  Volume 1, Issue 1  •  Published: 10 August 2025  •  Updated: 15 June 2026 Case Series & Mechanistic Review Compiled tumour marker responses, radiologic outcomes, and mechanisms of anti-cancer action across an international patient cohort Last updated: 15 June 2026 DOI: pending  •  Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Stage 4 PDAC: A Compiled Case Series of 28 Patients. OneDayMD Integr Oncol Rev. 2025;1(1). Updated June 2026. Evidence Classification All case reports in this series represent CEBM Level 4–5 evidence (case reports and expert opinion). This compilation is hypothesis-generating. No randomised controlled trials of ivermectin, fenbendazole, or mebendazole for pancreati...